These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11154621)

  • 21. Hydroxyurea as part of a salvage regimen for heavily pretreated patients with advanced HIV infection.
    Grunke M; Dechant C; Löw P; Rascu A; Kalden JR; Harrer T
    J Acquir Immune Defic Syndr; 1999 Aug; 21(5):424-6. PubMed ID: 10458626
    [No Abstract]   [Full Text] [Related]  

  • 22. Dideoxyinosine-induced pancreatitis in human immunodeficiency virus-infected children.
    Levin TL; Berdon WE; Tang HB; Haller JO
    Pediatr Radiol; 1997 Feb; 27(2):189-91. PubMed ID: 9028860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Editorial comment: drug-drug interactions, hepatitis C, and mitochondrial toxicity.
    Glesby MJ; Gerber JG
    AIDS Read; 2003 Jul; 13(7):346-7. PubMed ID: 12889453
    [No Abstract]   [Full Text] [Related]  

  • 24. Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide.
    Vila J; Nugier F; Barguès G; Vallet T; Peyramond D; Hamedi-Sangsari F; Seigneurin JM
    Lancet; 1997 Aug; 350(9078):635-6. PubMed ID: 9288048
    [No Abstract]   [Full Text] [Related]  

  • 25. Incidence of pancreatitis in HIV-infected patients: comment on findings in EuroSIDA cohort.
    Fessel J; Hurley LB
    AIDS; 2008 Jan; 22(1):145-7. PubMed ID: 18090403
    [No Abstract]   [Full Text] [Related]  

  • 26. Hydroxyurea and hepatitis.
    Shuster J
    Nursing; 2000 May; 30(5):77. PubMed ID: 10855204
    [No Abstract]   [Full Text] [Related]  

  • 27. Didanosine: an updated review of its use in HIV infection.
    Perry CM; Noble S
    Drugs; 1999 Dec; 58(6):1099-135. PubMed ID: 10651392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks.
    Paton NI; Aboulhab J
    HIV Med; 2005 Jan; 6(1):13-20. PubMed ID: 15670247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART).
    Stebbing J; Nelson M; Orkin C; Mandalia S; Bower M; Pozniak A; Gazzard B
    J Antimicrob Chemother; 2004 Mar; 53(3):501-5. PubMed ID: 14762056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toxic interaction of didanosine and acetaminophen leading to severe hepatitis and pancreatitis: a case report and review of the literature.
    Lederman JC; Nawaz H
    Am J Gastroenterol; 2001 Dec; 96(12):3474-5. PubMed ID: 11774996
    [No Abstract]   [Full Text] [Related]  

  • 31. Hydroxyurea plus didanosine as maintenance therapy for HIV-infected patients on long-term successful highly active antiretroviral therapy.
    Barreiro P; de Mendoza C; Camino N; García-Benayas T; Blanco F; Núñez M; González-Lahoz J; Soriano V
    HIV Clin Trials; 2003; 4(6):361-71. PubMed ID: 14628279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency.
    Lori F; Pollard RB; Whitman L; Bakare N; Blick G; Shalit P; Foli A; Peterson D; Tennenberg A; Schrader S; Rashbaum B; Farthing C; Herman D; Norris D; Greiger P; Frank I; Groff A; Lova L; Asmuth D; Lisziewicz J
    AIDS Res Hum Retroviruses; 2005 Apr; 21(4):263-72. PubMed ID: 15943568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized study of the safety and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1. American Foundation for AIDS Research Community-Based Clinical Trials Network.
    Hellinger JA; Iwane MK; Smith JJ; Fleishman AN; Torres RA; Schrader S; Perez G; Cohen CJ; Skowron G; Giordano MF; Accetta G; Cooper EC; Frost KR
    J Infect Dis; 2000 Feb; 181(2):540-7. PubMed ID: 10669337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unexpected drug interactions and adverse events with antiretroviral drugs.
    Moyle G; Boffito M
    Lancet; 2004 Jul 3-9; 364(9428):8-10. PubMed ID: 15234836
    [No Abstract]   [Full Text] [Related]  

  • 35. Acute pancreatitis associated with different combination therapies in patients infected with human immunodeficiency virus.
    Guo JJ; Jang R; Louder A; Cluxton RJ
    Pharmacotherapy; 2005 Aug; 25(8):1044-54. PubMed ID: 16207094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hydroxyurea and HIV infection].
    Nkoghe D; Kola L; Léonard P; Demonty J; Moutschen M
    Rev Med Liege; 2000 Jul; 55(7):721-4. PubMed ID: 11014107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydroxyurea reduces the 50% inhibitory concentration of didanosine in HIV-infected cells.
    Rana KZ; Simmons KA; Dudley MN
    AIDS; 1999 Oct; 13(15):2186-8. PubMed ID: 10546884
    [No Abstract]   [Full Text] [Related]  

  • 38. Mitochondrial toxic effects and ribavirin.
    Salmon-Céron D; Chauvelot-Moachon L; Abad S; Silbermann B; Sogni P
    Lancet; 2001 Jun; 357(9270):1803-4. PubMed ID: 11407389
    [No Abstract]   [Full Text] [Related]  

  • 39. Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns.
    Lisziewicz J; Foli A; Wainberg M; Lori F
    Drug Saf; 2003; 26(9):605-24. PubMed ID: 12814330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters.
    Lori F; Rosenberg E; Lieberman J; Foli A; Maserati R; Seminari E; Alberici F; Walker B; Lisziewicz J
    AIDS Res Hum Retroviruses; 1999 Oct; 15(15):1333-8. PubMed ID: 10515148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.